Sanofi SA
SNY:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 52.34 | -0.74 -1.39% | 3.38% | 516,137 | 754.0K |
Market data is delayed by at least 20 minutes.
Latest News Headlines for Sanofi SA
Approvals, FDA Response Letters, New Drug Applications, Collaborations, and Positive Opinions Boost Major Drug Portfolios - Research Report on Pfizer, Merck, GSK, AstraZeneca, and Sanofi
View more recent headlines
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, July 15, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), GlaxoSmithKline plc (NYSE: GSK), AstraZeneca PLC (NYSE: AZN), and Sanofi (NYSE: SNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Company Background
Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company based in France. The Company discovers, develops and distributes therapeutic solutions focused on patients' needs. The Company focuses on the field of healthcare with six growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets and animal health. The Company has a portfolio of prescription drugs, vaccines, generics and consumer healthcare products. The Company is active domestically and abroad, including other European countries, North and Latin Americas, Asia, Africa and Middle East. In December 2012, Sanofi announced that it completed the divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International, Inc. In April 2013, the Company inaugurated its logistics platform in Casablanca, Morocco.
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 52.00 | Previous Close 53.08 |
Day High 52.56 | Day Low 51.94 |
52wk High/Date 55.94 / 5/28/2013 | 52wk Low/Date 36.62 / 7/24/2012 |
% off 52wk High -6.44% | % off 52wk Low 42.93% |
Beta (5 Yr) 0.9 | Market Capitalization 138.5B |
Shares Outstanding 2.6B | Volatility Avg 39.18 |
EPS(TTM) 2.05 | P/E Ratio 25.6x |
Dividend Announcement 2/12/2013 | Dividend Yield 3.38% |
Ex-Date 5/6/2013 | Date of Record 5/8/2013 |
Payable 1.7925 - ANN | Payable Date 6/5/2013 |
Last Trade as of 7/19/2013 4:02 PM ET | |
SNY Sanofi SA vs. Peers
| Peers | |
|---|---|
SNY Sanofi SA | 10.47% |
Abbott Laboratories | 14.45% |
Bristol Myers Squibb Co. | 35.59% |
Eli Lilly & Co. | 2.60% |
SNY Sanofi SA | 3.42% |
Abbott Laboratories | 1.56% |
Bristol Myers Squibb Co. | 3.17% |
Eli Lilly & Co. | 3.87% |
SNY Sanofi SA | -1.39% |
Abbott Laboratories | 0.48% |
Bristol Myers Squibb Co. | 0.55% |
Eli Lilly & Co. | 1.36% |